Latest News
Pioneering medical radioisotope production
Southern Cross Medical Radioisotopes Pty Ltd (SCMR) is dedicated to revolutionising the medical industry by pioneering breakthrough alpha-emitter production (Ac-225), as well as a number of other radioisotopes in Australia.
Our vision is to establish Australia as a global leader in medical radioisotope production, ensuring reliable access to life-saving cancer therapies. We are committed to building a high-value sovereign medical radioisotope industry, fostering innovation, and making a meaningful impact on patient care.
Learn about our journey and the innovative services we offer that set us apart from others in the industry. Let us illuminate the path towards a brighter future in medical radioisotope production.
Our Projects
SCMR is developing a sovereign production hub utilising high-power electron accelerators. By establishing a vertically integrated supply chain, from raw material extraction to final radioisotope synthesis, we provide a scalable, reactor-free alternative to traditional nuclear medicine. Our current focus is on the commissioning of high-purity medical radioisotope production lines to meet the urgent needs of the global oncology market.
Medical Radioisotopes
Future
Targeted Alpha Therapy (TAT)
Targeted Alpha Therapy (TAT) represents the frontier of precision oncology. By harnessing high-energy alpha particles, TAT destroys cancer cells with sub-cellular accuracy while sparing surrounding healthy tissue.
SCMR is at the centre of this revolution, providing the critical, high-purity radioisotopes, led by Actinium-225, required to power these next-generation treatments and transform patient outcomes globally.